[1] |
胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
|
[2] |
国家卫生健康委员会.健康中国行动(2019-2030年)[EB/OL].[2020-03-09].http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.
|
[3] |
燕声.低钠替代盐可防心血管病[J].保健时报,2020,4(4):56-57.
|
[4] |
平海芹,周晓阳.盐敏感性高血压发病机制与治疗的研究进展[J].广西医学,2020,42(7):872-874.
|
[5] |
中国医师协会全科医师分会.沙库巴曲缬沙坦钠在基层心血管疾病临床应用的专家共识[J].中国全科医学,2021,24(23):2885-2890,2897.
|
[6] |
陈晓平,崔兆强,林金秀,等.《2020 国际高血压学会全球高血压实践指南》解读[J].中国医学前沿杂志,2020,12(5):54-60.
|
[7] |
唐欣颖,匡泽民,卢玺峰.中枢神经系统肾素(原)受体参与高血压发病机制的研究进展[J].中国卒中杂志,2019,12(14):1279-1282.
|
[8] |
Richardson SI,Freedman BI,Ellison DH,et al.Salt sensitivity:a review with a focus on non-Hispanic blacks and Hispanics[J].J Am SocHypertens,2018,7(2):170-179.
|
[9] |
Laffer CL,Scott RC 3rd,Titze JM,et al.Hemodynamics and salt-and-water balance link sodium storage and vascular dysfunction in salt-sensitive subjects[J].Hypertension,2016,68(1):195-203.
|
[10] |
肖东斌,耿肖囡,惠学志.沙库巴曲缬沙坦治疗老年及盐敏感性高血压的新进展[J].心血管病学进展,2019,40(4):540-543.
|
[13] |
国家卫生计生委合理用药专家委员会.高血压合理用药指南(第2 版)[J].中国医学前沿杂志(电子版),2017,9(7):28-126.
|
[14] |
中国高血压联盟《动态血压监测指南》委员会.2020 中国动态血压监测指南[J].中国医学前沿杂志(电子版),2021,13(3):34-51.
|
[11] |
Kusaka H,Sueta D,Koibuchi N,et al.LCZ696,angiotensinⅡreceptor-ne-prilysininhibitor,ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone[J].Am J Hypertens,2015,28(12):1409-1417.
|
[12] |
Wang TD,Tan RS,Lee HY,et al.Effects of sacubitril /valsartan (LCZ696) on natriuresis,diuresis,blood pressures,and NT-proBNP in salt-sensitive hy-pertension[J].Hypertension,2017,69(1):32-41.
|
[15] |
Katsuya T,Ishikawa K,Sugimoto K,et al.Salt sensitivity of Japanese from the viewpoint fgenepoly morphism[J].Hypertens Res,2019,26(7):521-525.
|